Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
32.37 USD | -5.71% | +1.89% | -21.36% |
05-08 | Oppenheimer Adjusts Arvinas Price Target to $70 From $80, Maintains Outperform Rating | MT |
05-07 | Arvinas Shares Up After Q1 Net Loss Narrows | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- For the past twelve months, EPS forecast has been revised upwards.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- Based on current prices, the company has particularly high valuation levels.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-21.36% | 2.35B | C- | ||
+2.93% | 106B | B+ | ||
+7.02% | 23.47B | B | ||
-14.60% | 21.9B | B+ | ||
-7.05% | 18.77B | A- | ||
-38.55% | 17.85B | A- | ||
-8.83% | 16.78B | B | ||
+5.51% | 14.41B | C+ | ||
+37.49% | 12.86B | C+ | ||
+329.39% | 8.78B | - | D+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- ARVN Stock
- Ratings Arvinas, Inc.